Your browser doesn't support javascript.
loading
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida, Hanae; Shimizu, Toshio; Nishino, Makoto; Nakamura, Yoshiaki; Yazaki, Shu; Katsuya, Yuki; Sato, Jun; Koyama, Takafumi; Iwasa, Satoru; Sudo, Kazuki; Kondo, Shunsuke; Yonemori, Kan; Shitara, Kohei; Shiono, Satoshi; Matsuoka, Daiko; Yasuda, Keisuke; Otake, Yohei; Suzuki, Takuya; Takase, Takao; Takashima, Shuya; Yamaguchi, Kohei; Semba, Taro; Yamamoto, Noboru.
Afiliación
  • Ida H; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Nishino M; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Nakamura Y; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Yazaki S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Katsuya Y; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Sato J; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Iwasa S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Sudo K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Kondo S; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Shitara K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Shiono S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Matsuoka D; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Yasuda K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Otake Y; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Suzuki T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Takase T; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Takashima S; Oncology Early Clinical Operation II, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Yamaguchi K; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Semba T; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Yamamoto N; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
Cancer Res Commun ; 3(7): 1189-1199, 2023 07.
Article en En | MEDLINE | ID: mdl-37435605
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Alcaloides de la Vinca / Neoplasias Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Alcaloides de la Vinca / Neoplasias Límite: Humans Idioma: En Revista: Cancer Res Commun Año: 2023 Tipo del documento: Article País de afiliación: Japón